Boron platform
AN2’s boron chemistry platform targets novel molecular sites to create medicines for infectious diseases and cancer.
an2therapeutics.comCrawled Oct 30, 2026
AN2’s boron chemistry platform targets novel molecular sites to create medicines for infectious diseases and cancer.
AN2-502998 is AN2's investigational oral treatment for Chagas disease, a neglected disease affecting millions with limited treatment options.
AN2 Therapeutics conducts clinical trials in an effort to bring boron-based medicines to patients with critical unmet needs. Find recruiting AN2 studies at ClinicalTrials.gov.
AN2's oral antibiotic epetraborole (EBO) could potentially treat M. abscessus, a multidrug-resistant lung infection with treatment success rates <50% and no FDA-approved therapies.
Robust pipeline of investigational boron-based medicines targeting polycythemia vera, Chagas disease, melioidosis, M. abscessus, and cancer with novel mechanisms.
Epetraborole is AN2’s investigational oral boron-based treatment for polycythemia vera that potentially modulates red cell production via a novel mechanism.
MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 9, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for
Funding from Gates Foundation supports continued advancement of boron-based LeuRS inhibitors for the treatment of tuberculosis MENLO PARK, Calif. --(BUSINESS WIRE)--Sep. 28, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and
Abstracts highlight epetraborole’s potential beneficial effects on hematological profile across clinical and nonclinical studies MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 31, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and
Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease; Enrollment expected to begin in 1Q26 with
MENLO PARK, Calif. --(BUSINESS WIRE)--Sep. 16, 2026-- AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor,
Join AN2 Therapeutics' team of passionate visionaries developing breakthrough medicines.
Req #: PM-1052 Location: Remote, with occasional meeting attendance in Menlo Park, CA Reports To: Executive Director, Program Leadership & Alliance Management Employment Type: Full-time (30–40 hrs/week) consultancy with potential to convert to employment About AN2 Therapeutics AN2 Therapeutics (AN2) is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from […]
AN2 Therapeutics aims to discover and develop boron-based medicines for diseases affecting millions.
AN2 Therapeutics uses boron chemistry to develop medicines for its pipeline.
AN2 Therapeutics develops medicines through its boron chemistry platform for infectious diseases and cancer.